A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

被引：0

作者：

Helmut Friess

Jan M Langrehr

Helmut Oettle

Jochen Raedle

Marco Niedergethmann

Christian Dittrich

Dieter K Hossfeld

Herbert Stöger

Bart Neyns

Peter Herzog

Pascal Piedbois

Frank Dobrowolski

Werner Scheithauer

Robert Hawkins

Frieder Katz

Peter Balcke

Jan Vermorken

Simon van Belle

Neville Davidson

Albert Abad Esteve

Daniel Castellano

Jörg Kleeff

Adrien A Tempia-Caliera

Andreas Kovar

Johannes Nippgen

机构：

[1] University of Heidelberg,Department of General Surgery

[2] Charité,Department of General and Transplantation Surgery

[3] Virchow-Clinic,Department of Hematology and Oncology

[4] Charité,Department of Medicine II

[5] Virchow-Clinic,Department of Surgery

[6] University of Frankfurt Hospital,Ludwig Blotzmann

[7] University Hospital Mannheim,Institute for Applied Cancer Research (LBI

[8] Kaiser Franz Josef-Spital,ACR Vienna)

[9] University Hospital Hamburg-Eppendorf,Department of Oncology/Hematology

[10] Medical University of Graz,Department of Internal Medicine, Division of Oncology

[11] Oncology Center,Department of Medical Oncology

[12] Vrije Universiteit Brussel,Department of Gastroenterology

[13] Reinhardt Nieter Krankenhaus,Department of Medical Oncology

[14] Henri Mondor Hospital,Department of Visceral, Thoracic and Vascular Surgery

[15] University Hospital Carl Gustav Carus,Department of Internal Medicine I, Division of Clinical Oncology

[16] Technical University of Dresden,Department of Medical Oncology

[17] University Hospital of Vienna,Department of Medicine V

[18] Paterson Institute for Cancer Research,Department of Medicine

[19] University of Manchester,Department of Oncology

[20] Clinic Darmstadt,Department of Oncology

[21] Clinic of the City of St. Poelten,Department of Medicine

[22] University Hospital Antwerpen,Department of Oncology

[23] University Hospital Gent,Department of Oncology

[24] St John's Hospital,Department of Pharmacology and Pharmacokinetics

[25] Hospital Germans Trias i Pujol,Medical Center of Excellence Oncology

[26] Hospital Universitario 12 de Octubre,undefined

[27] Merck KGaA,undefined

[28] Merck KGaA,undefined

来源：

BMC Cancer | / 6卷

关键词：

Pancreatic Cancer; Gemcitabine; Serum Vascular Endothelial Growth Factor; National Cancer Institute Common Toxicity Criterion; Gemcitabine Group;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 228 条

[1] Eskens FA(2003)Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours Eur J Cancer 39 917-926
[2] Dumez H(1996)Role of integrins in angiogenesis Eur J Cancer 32A 2423-2429
[3] Hoekstra R(1996)Role of integrins in angiogenesis Eur J Cancer 32A 2423-2429
[4] Perschl A(1994)Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 264 569-571
[5] Brindley C(1995)Definition of two angiogenic pathways by distinct alpha v integrins Science 270 1500-1502
[6] Bottcher S(2001)Integrin activation controls metastasis in human breast cancer Proc Natl Acad Sci USA 98 1853-1858
[7] Brooks PC(2003)Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin Mol Cancer Res 1 810-819
[8] Brooks PC(2002)alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin Int J Cancer 98 690-697
[9] Brooks PC(2003)Specific alpha v integrin receptors modulate K1735 murine melanoma cell behavior Biochem Biophys Res Commun 308 814-819
[10] Clark RA(1998)Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer Clin Cancer Res 4 2625-2634

← 1 2 3 4 5 6 7 8 9 10 →